Cellestis Shareholders OK Acquisition by Qiagen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shareholders of Australian firm Cellestis have approved the proposed acquisition of the firm by Qiagen.

The terms of the deal, which were amended last month to increase the total amount of consideration being paid, was overwhelmingly approved by Cellestis' shareholders with 92 percent of votes in favor of the deal. Roughly 73.9 million votes were cast in favor of the amended scheme, and around 6.5 million votes were against the proposal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."